BioGaia launches BioGaia Osfortis – a new product for the prevention of osteoporosis

“Osteoporosis is a common, global disease. Consequently, a way of maintaining good bone health and preventing osteoporosis constitutes an important focus area for BioGaia. I am very happy that our partner Everidis will launch BioGaia Osfortis in the USA. It is an important market with great potential for this product. Step by step more markets will launch BioGaia Osfortis,” says Isabelle Ducellier, CEO of BioGaia.

Clinically documented effects on bone health
In June 2018 a randomized, double-blind, placebo-controlled study with BioGaia’s probiotic strain Lactobacillus reuteri ATCC PTA 6475 was published, showing that loss in bone density was halved in the probiotic group compared to those given placebo. 90 older women with low bone density were included in the study which was conducted at the University of Gothenburg.

Osteoporosis – a silent disease
Bone loss usually occurs gradually over the years, most often without symptoms. A fracture is usually the first sign of the disease, and typically occurs in the hip, spine or wrist. It is estimated that worldwide one in three women and one in five men over the age of 50 are at risk of suffering a fracture caused by osteoporosis. The greatest risk factors are old age, previous fracture, low bone density and heredity. In women, estrogen also plays a decisive role. When estrogen levels drop after menopause, bone density decreases more rapidly.

Osteoporosis often affects the individual’s quality of life in a profound way, but it also constitutes a major burden for society. Preventing osteoporosis is therefore beneficial from many aspects.

Latest press releases from BioGaia
04-05-2019 Notice to attend the Annual General Meeting of BioGaia AB (publ)
03-25-2019 BioGaia publishes annual report for 2018 
03-18-2019 Finland first market to launch BioGaia Protectis capsules